anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A therapeutic composition, useful in muscle regeneration for the treatment of myopathy in metazoan animals, comprise one or more dinitramine compounds of the formula <FORM:1113702/A5-A6/1> wherein each R independently represents H, NH4 or an alkali metal (i.e. Na, K or Li) and at least one R is hydrogen or both R's are identical, all occurences of alkali metal in a compound being the same, and a pharmaceutically acceptable diluent or carrier.  Preferred nitramines are: N,N1 - dinitroethylenediamine and N,N1 - diammonium - N,N1 - dinitroethylenediamine.  Administration may be by oral or anal introduction, intravascular injection or injection into body cavities or tissues or external application.  The composition may be in the form of tablets, liquid, pellets, powder, chewing gum, gelatin capsules or microcapsules, salve, paste, lotion, or preferably it is mixed with the grain ration or other animal feed compositions.  Feed compositions may contain 0.0001 to 30% by weight of the active ingredient.  The composition may also be formulated as concentrates containing 5-98% by weight of dinitramine compounds.  The composition can also contain other biologically active materials such as vitamins or other dietary supplements, hormones or other growth regulants and/or stimulants.
This is a multicentre, randomised, sham-controlled, observer blinded trial. Patients at high clinical risk for cardiovascular events and scheduled to undergo major abdominal surgery will be enrolled. A total of 766 patients are randomised (1:1 ratio) to receive RIPC or no RIPC (control) before anaesthesia induction. RIPC will comprise four alternating cycles of cuff inflation for 5 min to 200 mm Hg and deflation for 5 min. In controls, the identical looking cuff will be placed around the arm but not actually inflated for 40 minutes. The primary outcome was myocardial injury after surgery within three days of surgery. The secondary outcomes were peak plasma hs-cTnT and total hs-cTnT release during the first three days after surgery, hs-cTnT above the prognostically important thresholds, length of hospital stay after surgery, and length of stay in the intensive care unit, myocardial infarction, major adverse cardiovascular events, cardiac-related death and all cause death within 30 days, 6 months, 1 year and 2 years after surgery, postoperative morbidity and adverse events within 30 days after surgery.
The intervention group of school-aged children will receive education on the F.A.S.T. (Face, Arm, Speech and Time) acronym, additional signs and symptoms of stroke and the need for immediate activation of Emergency Medical Services (EMS) by calling 911.
As outlined ECOG performance status will be recorded at the time of registration without the subject's involvement. Quality of life, treatment satisfaction, distress and peacefulness will also be recorded at baseline. subjects will watch the goals-of-care (GOC) video (described in detail in the next paragraph) and then be given the narrative question stem vetted/assessed in part 1 including any changes made to that stem in the process of Part 1 testing. Subjects in P-COCC arm will then be contacted for a telephone interview and audio-taping of their narrative. Interviews will be semi- structured and based off the narrative stem that subjects were previously given for review. Interviews will last approximately 30-45 minutes and will be conducted by staff from the MSKCC Department of Psychiatry \& Behavioral Sciences.
The invention relates to a nifuratel-nysfungin vaginal expandable suppository and its preparation method and detection method. The nifuratel-nysfungin vaginal expandable suppository comprises a drug-containing matrix comprising nifuratel, nysfungin and a matrix, and also comprises an expandable carrier. Through use of colloidal silicon dioxide in the drug-containing matrix, nysfungin hygroscopicity is reduced and suppository stability is improved. Nifuratel, nysfungin, povidone and hydroxypropyl methylcellulose form a skeleton clathrate so that nysfungin and nifuratel stability are further improved and the time of action produced by the active components on the vagina is further prolonged. Propylene glycol monostearate and Tween 80 can promote absorption of the active components by the vagina and suppository bioavailability is improved. The nifuratel-nysfungin vaginal expandable suppository utilizes seven novel lead-edge technologies and has the advantages of drug liquid leakage prevention, high stability, lasting curative effects and secondary infection prevention.
PURPOSE:To prepare a composition for oral cavity application, having remarkably improved foamability and excellent stability, feeling to the mouth, and juice effect, and useful as a raw material of tooth paste, etc., by using a fatty acid ester of a sugar alcohol such as lactitol and an N-long-chain-acyl amino acid as main components. CONSTITUTION:A composition for oral cavity application, containing (A) a fatty acid ester or lactitol or a sugar alcohol of formula (n is 1-6) and (B) an N-long- chain-acyl amino acid or its salt. The excellent characteristics of the component (A) are fully exhibited in the composition. The composition has remarkably improved foamability, and excellent stability when compounded to a tooth paste, etc., feeling to the mouth, e.g. taste, flavor, etc., and juice effect. Preferable (B) component is glutamic acid N-substituted with a 8-20C acyl group, and the (A) component has pref. a 8-20C acyl group and an average degree of esterification of 0.5-3.0. The amounts of the components are, 1-50pts.wt. of (A) (0.1-5wt% of the whole composition) and 1-2pts.wt. of (B) (0.05-2wt% of the whole composition).
Patients and caregivers attend a CRCweb intervention over 8 weeks. Patients and caregivers complete interviews and surveys throughout the trial.
Include ten young adult orthodontic patients who are treated by using fixed orthodontic appliances followed by the type IV Herbst appliance (mini plate anchored appliance). The age of patients will be (18-20y).
Chlorzoxazone containing products are usually well tolerated. It is possible in rare instances that chlorzoxazone may have been associated with gastrointestinal bleeding. Drowsiness, dizziness, lightheadedness, malaise, or over-stimulation may be noted by an occasional patient. Rarely, allergic- type skin rashes, petechiae, or ecchymoses may develop during treatment.

Angioneurotic edema or anaphylactic reactions are extremely rare. There is no evidence that the drug will cause renal damage.

Rarely, a patient may note discoloration of the urine resulting from a phenolic metabolite of chlorzoxazone. This finding is of no known clinical significance.

To report SUSPECTED ADVERSE EVENTS, contact Cintex Services at 1-855-899-4237 or FDA at 1-800- FDA-1088 or http://www.fda.gov/ for voluntary reporting of adverse reactions.
Based on spontaneous postmarketing reports, acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with liraglutide, one of the components of XULTOPHY 100/3.6. In glycemic control trials of liraglutide, there have been 13 cases of pancreatitis among liraglutide-treated patients and 1 case in a comparator (glimepiride) treated patient (2.7 vs. 0.5 cases per 1000 patient-years). Nine of the 13 cases with liraglutide were reported as acute pancreatitis and four were reported as chronic pancreatitis. In one case in a liraglutide-treated patient, pancreatitis, with necrosis, was observed and led to death; however clinical causality could not be established. Some patients had other risk factors for pancreatitis, such as a history of cholelithiasis or alcohol abuse.

After initiation of XULTOPHY 100/3.6, observe patients carefully for signs and symptoms of pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back and which may or may not be accompanied by vomiting). If pancreatitis is suspected, XULTOPHY 100/3.6 should promptly be discontinued and appropriate management should be initiated. If pancreatitis is confirmed, restarting XULTOPHY 100/3.6 is not recommended. 

Liraglutide, one of the components of XULTOPHY 100/3.6, has been studied in a limited number of patients with a history of pancreatitis. It is unknown if patients with a history of pancreatitis are at higher risk for development of pancreatitis on liraglutide.
Patients receive a lifestyle intervention, "Survivors of Uterine Cancer Empowered by Exercise and Healthy Diet (SUCCEED)", on a group and individual basis consisting of nutrition, exercise, and behavioral modification counseling from a physician, psychologist, registered dietitian, and physical therapist. Sixteen group sessions will be conducted (10 weekly, 6 bi-weekly) for 6 months. Weight and body mass index, satisfaction with study treatment, and exercise/activity logs are assessed weekly and biweekly. Patients receive additional feedback and support during the weeks not met in a group, including newsletters and telephone and e-mail contact.
FIELD: medicine. ^ SUBSTANCE: invention belongs to chemical and pharmaceutical industry, notably to design of plant-origin enterosorbent. Enterosorbent are granules, containing peat moss Sphagnum fuscum. Granules are produced by Sphagnum fuscum grass sod disintegration up to particles 0,1-0,3 mm which are subsequently mixed with 10% aqueous low molecular polyvinylpyrrolidone, granulated, dried and granulated again up to granules humidity not higher 30-35%. ^ EFFECT: produced by this method enterosorbent is low-toxic. ^ 2 tbl
Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS) are hyperglycemic crises sharing similar clinical features including hyperglycemia, dehydration and electrolytes abnormalities. Hyperglycemia results from relative deficient circulating insulin and oversecretion of glucagon, catecholamines, cortisol, and growth hormone. Glycosuria induced osmotic diuresis leads to dehydration and electrolyte abnormalities. Diabetic ketoacidosis is also characterized by increased gluconeogenesis, lipolysis, ketogenesis, and decreased glycolysis.\[1\] In critically ill and mentally obtunded patients with DKA or hyperosmolar hyperglycemia, continuous intravenous insulin is the standard of care.\[2\] Administration of subcutaneous insulin glargine during intravenous insulin infusion shortened the time of DKA correction and significantly decreased hyperglycemia after discontinuation of the intravenous insulin. \[3, 4\]The differences in rebound hyperglycemia rates were highly significant for at least 12 hours after transition to subcutaneous insulin regimens in the DKA and non-DKA patients as well as in organ transplant patients receiving steroids. \[4\] However, the previous studies only enrolled small numbers of patients(without Asian population) and excluded newly diagnosed hyperglycemia or critical illness and pregnant women. The safety and efficacy of basal insulin during intravenous insulin infusion for hyperglycemic crisis patients under critical care is still unknown.

The investigators assumed that concurrent basal insulin subcutaneous injection and intravenous insulin infusion for critically ill DKA and HHS patients would shorten the time of hyperglycemic crisis correction and achieved better glycemic control(decrease hypoglycemia and rebound hyperglycemia).
The utility model relates to a tablet with female patterns, which is characterized in that the integral shape of the tablet is cylinder-shaped. The diameter of the bottom surface of a cylinder is larger than the height of the cylinder. Female animal patterns are respectively carved on both bottom surfaces of the cylinder. The utility model can become integration independently. The utility model with the advantages of anti-counterfeiting function, anti-forging function, etc. is convenient for users to distinguish the varieties of medicines.
Liothyronine sodium tablets, USP contain the active ingredient, liothyronine (L-triiodothyronine or LT3), a synthetic form of a thyroid hormone liothyronine in sodium salt form. It is chemically designated as L-Tyrosine, O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-, monosodium salt. The molecular formula, molecular weight and structural formula of liothyronine sodium are given below.

Liothyronine sodium tablets, USP contain liothyronine sodium, USP equivalent to liothyronine in 5 mcg, 25 mcg, and 50 mcg. Inactive ingredients consist of calcium sulfate dihydrate, corn starch, gelatin, stearic acid, sucrose and talc.

FDA approved dissolution method differ from the USP dissolution method.
The invention relates to a process for the preparation of a concentrate of factor VIII-von Willebrand factor complex having high specific activity from non-cryoprecipitated plasma. The process comprises a pre-purification commenced by coagulating with barium chloride and adsorption on aluminium hydroxide. The process then comprises purification by chromatography on an anion exchange resin of the DEAE-Fractogel type. The process comprises a step of viral inactivation by the solvent/detergent treatment. The process also enables fibrinogen, albumin, immunoglobulins, antithrombin III, fibronectin and prothrombin complex to be recovered from the same plasma. The various concentrates obtained by the process are suitable for the therapeutic use.
Patients in the experimental arm will received azacytidine plus chidamide treatment. This regimen was repeated every 28 days.
PURPOSE:To shorten the waiting time of a patient by making it possible to connect a memory card to an apparatus main body apart from the memory in the apparatus main body and making it possible to read and write an arbitrary program and data. CONSTITUTION:A microcomputer 10 controls a probe driver 12 to allow a probe 13 to transmits an ultrasonic wave. The data received by the probe 13 is amplified by an amplifier 14 and further processed by a sample measuring circuit 15. This processed data is sent to a waveform and image display circuit 16 to be displayed on a display 17 as a waveform or an image and also sent to the microcomputer 10 which in turn controls a character and graphic display circuit 18 to display a necessary character or graphic on the display. A card interface 20 is connected to the microcomputer 10 to perform the exchange of data with a memory card 22 through a card connector 21. By this constitution, the waiting time of a patient is shortened and the reexamination of a measured result becomes easy.
1,191,385. Hydroxybenzothioxanhene derivatives. MERCK & CO. Inc. 24 April, 1968 [27 April, 1967], No. 51489/69. Divided out of 1,191,384. Heading C2C. Novel hydroxybenzothioxanthene derivatives of the general formula wherein B is a benzene ring fused in the [a] or [c] position, X is a bromine or chlorine atom and each R is a hydrogen atom or a C 1-6  alkyl group, are prepared by reaction of a benzothioxanthenone derivative of the general formula with a Grignard reagent of the general formula hal.Mg.CH 2 CH 2 CH 2 .N(R) 2 , wherein hal is a halogen atom, and hydrolysis of the resulting Grignard adduct. Benzothioxanthenone derivatives of the second general formula above are prepared by heating a naphthylthiobenzoic acid derivative of the general formula in the presence of a dehydrating agent of the polyphosphoric acid type. 5 - Chloro - 2 - (1 - or 2 - naphthylthio) benzoic acid is prepared by treatment of 5-chloroanthranilic acid with nitrous acid, followed by potassium iodide, and reaction of the resulting 2-iodo-5- chlorobenzoic acid with α- or #-naphthalenethiol, respectively.
This study aims to identify preoperative risk factors for iliopsoas tendonitis after total hip arthroplasty, a complication typically attributed to acetabular cup position and orientation, using a validated iliopsoas impingement detection simulation. Analyzing CT scans and X-rays of 448 patients using a validated preoperative planning protocol, patients were simulated for iliopsoas impingement and categorized into at-risk and not at-risk groups based on a prior validation study, with a 23% at-risk incidence. Implementing a propensity score matching algorithm to reduce covariate imbalance, we identified factors that may exacerbate risk of iliopsoas tendonitis. Parameters that were investigated included standing pelvic tilt, functional femoral rotation, and the difference between the planned acetabular cup diameter and native femoral head diameter (ΔC-NFH). Comparing pelvic tilt, we found a significant difference between the groups (at-risk: -6.0°, not at-risk: -0.7°; p << 0.01). A similar trend was noted for ΔC-NFH (at-risk: +5.7 mm, not at-risk: +5.1 mm; p = 0.01). Additional simulations of at-risk patients indicated increased anteversion of the acetabular cup reduces impingement risk more effectively than medialisation. These findings suggest that spinopelvic parameters may exacerbate iliopsoas irritation risk, underscoring their importance in preoperative planning and patient expectation management. Similar findings of a greater than 6 mm difference between cup size and native femoral head diameter being a significant risk for iliopsoas tendonitis have been observed before, underscoring its potential veracity. These results may provide surgeons with a simple threshold that can be used in determining a cup size to reduce the risk of iliopsoas tendonitis.
In this study the investigators aimed to investigate whether there is a relation between body weight and serum anti mullerian hormone levels in adults with polycystic ovary syndrome. For this purpose the investigators designed a prospective study including three groups. The diagnosis of polycystic ovary syndrome was made in the presence of ;oligo- and/or anovulation,clinical and/or biochemical signs of hyperandrogenism and polycystic ovaries. Clinical hyperandrogenism was defined by the presence of hirsutism , acne, or the presence of androgenic alopecia , biochemical hyperandrogenemia was defined as a serum level of total testosterone higher than 2.60 nmol/L, body mass index (BMI) was calculated as weight in kilograms divided by the square of height in meters. The patients were classified as obese with BMI ≥ 25 kg/m2 , adolescent patients were diagnosed 2 years after menarche in order to avoid the misdiagnosis of transitory functional hyperandrogenism and menstrual disorders during puberty. The all three groups are compared considering their serum AMH levels,lipid profiles, sex steroids and glycemic analyses.
The invention discloses a multi-substituted dihydropyridine-4-ketone compound, a preparation method and an application thereof, wherein a structure general formula of the compound is represented as formula I. The preparation method includes a step of carrying out an intermolecular cascade reaction between a functionalized alkenyl amide and isonitrile in an organic solution with a Lewis acid being a catalyst to efficiently obtain the dihydropyridine-4-ketone compound. By means of the method, multi-substituted dihydropyridine-4-ketone compounds having various substituent groups can be synthesized, wherein the multi-substituted dihydropyridine-4-ketone compounds having various substituent groups cannot be synthesized by other methods. The method is simple in operation and is high in yield. A product is easy to purify. The method has a good application prospect.
A two-phase cosmetic composition is provided packaged in a clear container. Within the container is an oil and an aqueous phase separated from one another but when shaken form a highly temporary, clear emulsion. One of the phases is colored with a dye while the other is ordinarily water white. Color stability may be enhanced through use of a UV protectant. A bead control agent may be included to eliminate unsightly bead formation on walls of the container. Sorbitan derivatives are useful for this purpose.
FIELD: medicine, anesthesiology, resuscitation, surgery. SUBSTANCE: one should inject 400 ml ozonized physiological solution into portal vein at ozone concentration of 4-5 mg/l beginning since the first day of postoperative period. Moreover, the number of seances correspond to 7-10 depending upon disease flow and clinicobiochemical values. The method in question enables to provide inactivation of toxic products before they enter the liver. EFFECT: higher efficiency of therapy. 3 dwg, 1 tbl
BACKGROUND AND PURPOSE: The triglyceride-glucose (TyG) index, a novel reliable biomarker for IR that incorporates blood glucose and triglyceride, is linked to intracranial atherosclerotic stenosis (ICAS). In this study, we aimed to further investigate the association between the TyG index and the outcomes of ICAS patients following extracranial-to-intracranial (EC-IC) bypass grafting.
METHODS: 489 ICAS patients who underwent EC-IC bypass between Jan 2009 and Jan 2022 at our hospital were retrospectively collected. The major adverse cardiac and cerebrovascular events (MACCEs), and anastomotic restenosis, both of which are critical factors leading to poor prognosis of ICAS patients after EC-IC bypass, were mainly recorded and analyzed. Kaplan-Meier survival curve and Log-rank tests were sequentially conducted. Cox regression model was used to investigate the association between the TyG index and MACCEs & anastomotic stenosis. C-statistics, continuous net reclassification improvement (NRI), and integrated discrimination improvement (IDI) evaluated the incremental predictive value of the TyG index.
RESULTS: A higher incidence of MACCEs and anastomotic stenosis was found in higher-tertile TyG index group. The TyG index was significantly associated with an increased risk of MACCEs and anastomotic stenosis, independent of confounding factors, with a value of HR (1.30, 95%CI 1.10-1.51, p < 0.001) and (1.27, 95%CI 1.16-1.40, p < 0.001) respectively. The area under the curve (AUC) in the model with the TyG index for predicting the occurrence of MACCEs and anastomotic stenosis were 0.708 (95%CI 0.665-0.748) and 0.731 (95%CI 0.689-0.770) respectively. The addition of the TyG index significantly improved the global performance of the baseline model according to the C-statistics, NRI, and IDI (All p < 0.05).
CONCLUSIONS: Higher TyG levels were associated with poorer outcomes in ICAS patients after EC-IC bypass. TyG could be a key factor in managing ICAS risk and standardizing the indications for EC-IC bypass.
Metformin will be prescribed before 20 weeks to 33+6 weeks, started at a daily dose of 500mg in the first week, and the daily dose is increased by 500mg per week to a maximum of 2000mg in week 4 (1000mg twice per day). Women will be asked to take the maximum tolerated dose if they experience side effects from the medication.